Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is a 2 part Phase I/II clinical trial evaluating the safety, tolerability and efficacy
of avelumab in combination with chemoradiation in patients with resectable esophageal and
gastroesophageal cancer.
Part 1: This is the run-in phase of the trial. This portion will determine the safety and
tolerability of avelumab in combination with chemoradiotherapy in 6 patients. The proposed
combination will be considered as safe if dose limiting toxicities are observed in at most 1
patient.
Part 2: This is a Phase 2 portion of the trial, which will evaluate the efficacy of the
proposed treatment regimen in patients with stage II/III resectable esophageal and
gastroesophageal cancer